Home >  Medicine MDTV >  Medicine Shorts >  Leptospirosis in central...

Leptospirosis in central & eastern Uttar Pradesh, an underreported disease

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-29 03:30 GMT   |   Update On 2022-08-29 07:46 GMT
Advertisement
Only a few studies are available which report the prevalence of leptospirosis in this State. Hence, this study was undertaken to know the status of the disease in central and eastern Uttar Pradesh.
A total of 143 serum and urine samples were collected from patients with acute febrile illness. All the serum samples were tested for Leptospira by rapid IgM antibody card and IgM ELISA and urine samples were tested by real-time polymerase chain reaction (RT-PCR) to detect Leptospira DNA. All positive and 10 per cent negative sera from ELISA and RT-PCR were sent to the ICMR-Regional Medical Research Centre, Port Blair for microscopic agglutination test.
Advertisement
Thirty eight i.e 26.6% out of 143 samples were positive for leptospirosis either by ELISA or RT-PCR. Positive results were 6% by Rapid card, 22% by IgM ELISA, 7% by microscopic agglutination test 7% by RT-PCR.
So In conclusion, leptospirosis was found to be one of the important causes for acute febrile illness in the central and eastern parts of Uttar Pradesh. The results of the present study suggest that it is necessary to increase diagnostic facility and awareness in clinicians for the screening of leptospirosis in acutely febrile patients to decrease morbidity and mortality associated with this disease.
Reference: Shukla S, Mittal V, Karoli R, Singh P, Singh A. Leptospirosis in central & eastern Uttar Pradesh, an underreported disease: A prospective cross-sectional study. Indian J Med Res. 2022 Jun 1. doi: 10.4103/ijmr.IJMR_1811_19. Epub ahead of print. PMID: 35647944.
Full View
Tags:    
Article Source : Indian Journal of Medical Research

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Reperfusion Therapy for STEMI in LMICs: A Clinical Consensus Discussion with Dr Thomas Alexander

Common cholesterol-lowering drugs may reduce risk of developing dementia: Study

Can Taking 4,000 Steps Just Once a Week Lower the Risk of Death and Heart Disease? Study Provides Clarity

Long-term Exercise Keeps Immune System Younger and Sharper: Study Finds

EASD 2025: First-Ever Guidelines Released to Address Diabetes Distress

DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings

Rare Disease Show - Episode 26: Understanding Pfeiffer Syndrome ft Dr. Roshan Daniel

Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial